Early and sustained improvements in patient-reported outcomes with tralokinumab in combination with topical corticosteroids as needed in moderate-to-severe atopic dermatitis

被引：0
|
作者：
Elewski, B. E. [1 ]
Staender, S. [2 ,3 ]
Zirwas, M. [4 ]
Silvestre, J. F. [5 ]
Kalia, S. [6 ,7 ,8 ]
Gutermuth, J. [9 ,10 ]
Mark, T. [11 ]
Tindberg, A. M. [11 ]
Silverberg, J. I. [12 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Univ Hosp Munster, Dept Dermatol, Munster, Germany
[3] Univ Hosp Munster, Interdisciplinary Competence Ctr Chron Pruritus K, Munster, Germany
[4] Prob Med Res, Columbus, OH USA
[5] Hosp Gen Univ Alicante, Dermatol Dept, Alicante, Spain
[6] Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC, Canada
[7] Vancouver Coastal Hlth, Vancouver, BC, Canada
[8] BC Childrens Hosp Res Inst, Vancouver, BC, Canada
[9] Univ Ziekenhuis Brussel, Dept Dermatol, Brussels, Belgium
[10] Vrije Univ Brussel, Brussels, Belgium
[11] LEO Pharma AS, Ballerup, Denmark
[12] George Washington Univ, Sch Med & Hlth Sci, Depat Dermatol, Washington, DC 20052 USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2021年 / 184卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
385
引用
收藏
页码：E83 / E84
页数：2
相关论文
共 50 条
  • [11] Tralokinumab real-world patient-reported outcomes in moderate-to-severe atopic dermatitis adult patients in the United States: 6-month interim analysis
    Lio, Peter
    Kim, Yestle
    Balu, Sanjeev
    Costantino, Halley
    Bates, Dawn
    Rene, Cassandra
    Lopez, Amanda
    Soung, Jennifer
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II50 - II51
  • [12] Dupilumab Improves Patient-Reported Outcomes (PROs) in a Phase 2 Study in Adults with Moderate-to-Severe Atopic Dermatitis
    Simpson, Eric
    Worm, Margitta
    Soong, Weily
    Blauvelt, Andrew
    Eckert, Laurent
    Wu, Richard
    Ardeleanu, Marius
    Graham, Neil
    Pirozzi, Gianluca
    Sutherland, E. Rand
    Mastey, Vera
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB167 - AB167
  • [13] Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
    Jonathan I. Silverberg
    David N. Adam
    Matthew Zirwas
    Sunil Kalia
    Jan Gutermuth
    Andreas Pinter
    Andrew E. Pink
    Andrea Chiricozzi
    Sebastien Barbarot
    Thomas Mark
    Ann-Marie Tindberg
    Stephan Weidinger
    American Journal of Clinical Dermatology, 2022, 23 : 547 - 559
  • [14] Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials
    Reich, K.
    DeLozier, A. M.
    Nunes, F. P.
    Thyssen, J. P.
    Eichenfield, L. F.
    Wollenberg, A.
    Terres, J. A. Ross
    Watts, S. D.
    Chen, Y-F
    Simpson, E. L.
    Silverberg, J., I
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1521 - 1530
  • [15] Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
    Silverberg, Jonathan, I
    Adam, David N.
    Zirwas, Matthew
    Kalia, Sunil
    Gutermuth, Jan
    Pinter, Andreas
    Pink, Andrew E.
    Chiricozzi, Andrea
    Barbarot, Sebastien
    Mark, Thomas
    Tindberg, Ann-Marie
    Weidinger, Stephan
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (04) : 547 - 559
  • [16] High burden of patient-reported ocular disorders and symptoms in adults with moderate-to-severe atopic dermatitis
    Weyne, J.
    Blauvelt, A.
    de Bruin-Weller, M.
    Prens, E.
    Asbell, P.
    Sierka, D.
    Chen, Z.
    Shumel, B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S53 - S53
  • [17] Atopic dermatitis: Patient characteristics and patient-reported outcomes on topical therapy
    Anderson, P.
    Austin, J.
    Lofland, J.
    Piercy, J.
    Joish, V.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S58 - S58
  • [18] Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis
    Merola, Joseph F.
    Butler, Daniel C.
    Mark, Thomas
    Schneider, Shannon
    Kim, Yestle
    Abuabara, Katrina
    JAMA DERMATOLOGY, 2023, 159 (10) : 1119 - 1123
  • [19] Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice
    Schloesser, Anne R.
    Shareef, Madena
    Olydam, Jill
    Nijsten, Tamar E. C.
    Hijnen, Dirk Jan
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (05) : 510 - 517
  • [20] Greater severity of atopic dermatitis (AD) is associated with poorer patient-reported outcomes among adults with moderate-to-severe AD
    Nyberg, Fredrik
    Hansen, Jes B.
    Andersen, Line
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 334 - 334
12345